The Life Sciences team advised the underwriting syndicate, Goldman Sachs, Citigroup and H.C. Wainwright & Co., in connection with the closing of DBV Technologies S.A. (NASDAQ: DBVT) approximately $81 million follow-on offering, including the full exercise of the underwriters’ option to purchase additional shares. The offering consisted of 2,447,500 ordinary shares in the form of 4,895,000 American Depositary Shares, sold in the United States, Canada and certain other countries outside Europe at a public offering price of $6.75 per ADS, and 3,552,500 ordinary shares, sold in Europe in a concurrent private placement at a price of €12.02 per ordinary share.
Based in France, DBV is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, their proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. DBV are advancing this unique technology to treat patients, including infants and children, suffering from severe food allergies.
The Goodwin team was led by partners Edwin O’Connor, Seo Salimi, James Barri, Brian Fairchild, Janet Andolina, Caroline Bullerjahn and Ettore Santucci, counsel Stephanie Philbin and associates William Magioncalda, Nicholas Reist, Yasee Zahedi, Tiffany Williamson, Olivia Uitto, Steven Tjoe and Alexander Plaum.
For additional details on the offering, please read the press release.